Rafiq Hasan

Rafiq Hasan is a prominent figure in the biotechnology and pharmaceutical sectors, currently serving as a Senior Advisor at BioGeneration Ventures (BGV). He holds a medical degree from the University of London and has extensive experience spanning over two decades in various roles within the pharmaceutical industry, including clinical development, medical affairs, and market access.23

Career Highlights

• Pharmaceutical Leadership: Dr. Hasan has held significant positions at major pharmaceutical companies, notably as the Global Head of Ophthalmology at Bayer and Novartis. During his tenure at Bayer, he was instrumental in the growth of the Eylea® product line, achieving over $2.5 billion in sales within five years and overseeing its launch in multiple indications.13
• Entrepreneurial Ventures: After his time in large pharma, he transitioned to leadership roles in biotech, including serving as CEO of Exact Therapeutics AS and later becoming CEO of Complement Therapeutics Ltd., a company focused on developing therapies for complement-driven diseases.12
• Current Role at BGV: As a Senior Advisor at BGV since January 2022, Dr. Hasan contributes to the firm’s mission of investing in early-stage European biotech companies. His expertise helps guide BGV's investment strategies and support for portfolio companies.24

Additional Roles

In addition to his advisory position at BGV, Dr. Hasan has been appointed to various boards, including Exonate Ltd., where he serves as a Non-Executive Director. His contributions are particularly valuable in advancing therapies for retinal diseases.3

Dr. Hasan's career reflects a strong commitment to advancing medical innovation and improving patient outcomes through strategic investments and leadership in biotechnology.